Lv4
538 积分 2024-04-21 加入
A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma
24天前
已完结
Structural Basis of Epitope Recognition by Heavy-Chain Camelid Antibodies
1个月前
已完结
Nanobodies: natural single-domain antibodies
1个月前
已完结
Recent advances in bispecific natural killer cell engagers for cancer immunotherapy
2个月前
已完结
The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics
3个月前
已完结
PD-1 signaling and PD-1 blockade-mediated tumor control are established at microvillar T cell contacts
3个月前
已完结
Research trends in the use of nanobodies for cancer therapy
6个月前
已完结
皖公网安备34019202002308
